Ann: ITL Launches more Blood Sector Products, page-9

I keep an eye on this too, I was a long term holder and sold during the sell down (though not at the peak unfortunately).
The six monthly reporting for continuing operations was not great, six monthly revenue of just over $10 millions and a loss of 0.2m versus 2.1m profit prior. But I still think it has great potential, I'm going to wait till the next reporting to review, even if it is positive, I think that there will be opportunity to buy in then.